ArticleOncotarget2017
Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma.Cancer letters · 2026Article
- Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review.Cancers · 2024Review
- Review
- DNA copy number profiles and systems biology connect chromatin remodeling and DNA repair in high-risk neuroblastoma.Genetics and molecular biology · 2024Article
- Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features.Journal of pathology and translational medicine · 2024Article
- Quantitative Diffusion-Weighted MRI of Neuroblastoma.Cancers · 2023Article
- Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma.Genome biology · 2022Article
- miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Article
- Molecular Basis and Clinical Features of Neuroblastoma.JMA journal · 2021Review
- An overview of neuroblastoma cell lineage phenotypes andExperimental biology and medicine (Maywood, N.J.) · 2020Review
- Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.Cancer communications (London, England) · 2020Article
- 19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis.NPJ genomic medicine · 2020Article
- Opportunities and challenges of circulating biomarkers in neuroblastoma.Open biology · 2019Review
- Subgrouping of Unfavorable Histology Neuroblastomas With Immunohistochemistry Toward Precision Prognosis and Therapy Stratification.JCO precision oncology · 2019Article
- Clinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma.Cancer informatics · 2019Article
- Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro.Nutrients · 2018Article
- Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.Drug design, development and therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To provide better insight into the genetic signatures of neuroblastomas, we analyzed 500 neuroblastomas (included specimens from JNBSG) using targeted-deep sequencing for 10 neuroblastoma-related genes and SNP arrays analysis. ALK expression was evaluated using immunohistochemical analysis in 259 samples. Based on genetic alterations, the following 6 subgroups were identified: groups A (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.